Tumor cells that were treated with EZH2 inhibitor alone or in combination with anti-PD1 had increased H2-K1, B2m, and Ifngr1 expression, and decreased expression of neutrophil-recruiting chemokines such as Cxcl3, Cxcl5, and Ppbp (a.k.a Cxcl7). The gene discussed is EZH2; the disease is neoplasm.